Engineering the Plant Factory for the Production of Biologics and Small-Molecule Medicines
Plant gene transfer achieved in the early ‘80s paved the way for the exploitation of the potential of gene engineering to add novel agronomic traits and/or to design plants as factories for high added value molecules. For this latter area of research, the term "Molecular Farming" was coine...
Saved in:
Superior document: | Frontiers Research Topics |
---|---|
: | |
Year of Publication: | 2017 |
Language: | English |
Series: | Frontiers Research Topics
|
Physical Description: | 1 electronic resource (377 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993546517104498 |
---|---|
ctrlnum |
(CKB)3800000000216394 (oapen)https://directory.doabooks.org/handle/20.500.12854/46423 (EXLCZ)993800000000216394 |
collection |
bib_alma |
record_format |
marc |
spelling |
Domenico De Martinis auth Engineering the Plant Factory for the Production of Biologics and Small-Molecule Medicines Frontiers Media SA 2017 1 electronic resource (377 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Frontiers Research Topics Plant gene transfer achieved in the early ‘80s paved the way for the exploitation of the potential of gene engineering to add novel agronomic traits and/or to design plants as factories for high added value molecules. For this latter area of research, the term "Molecular Farming" was coined in reference to agricultural applications in that major crops like maize and tobacco were originally used basically for pharma applications. The concept of the “green biofactory” implies different advantages over the typical cell factories based on animal cell or microbial cultures already when considering the investment and managing costs of fermenters. Although yield, stability, and quality of the molecules may vary among different heterologous systems and plants are competitive on a case-to-case basis, still the “plant factory” attracts scientists and technologists for the challenging features of low production cost, product safety and easy scale up. Once engineered, a plant is among the cheapest and easiest eukaryotic system to be bred with simple know-how, using nutrients, water and light. Molecules that are currently being produced in plants vary from industrial and pharmaceutical proteins, including medical diagnostics proteins and vaccine antigens, to nutritional supplements such as vitamins, carbohydrates and biopolymers. Convergence among disciplines as distant as plant physiology and pharmacology and, more recently, as omic sciences, bioinformatics and nanotechnology, increases the options of research on the plant cell factory. “Farming for Pharming” biologics and small-molecule medicines is a challenging area of plant biotechnology that may break the limits of current standard production technologies. The recent success on Ebola fighting with plant-made antibodies put a spotlight on the enormous potential of next generation herbal medicines made especially in the name of the guiding principle of reduction of costs, hence reduction of disparities of health rights and as a tool to guarantee adequate health protection in developing countries.Plant gene transfer achieved in the early ‘80s paved the way for the exploitation of the potential of gene engineering to add novel agronomic traits and/or to design plants as factories for high added value molecules. For this latter area of research, the term "Molecular Farming" was coined in reference to agricultural applications in that major crops like maize and tobacco were originally used basically for pharma applications. The concept of the “green biofactory” implies different advantages over the typical cell factories based on animal cell or microbial cultures already when considering the investment and managing costs of fermenters. Although yield, stability, and quality of the molecules may vary among different heterologous systems and plants are competitive on a case-to-case basis, still the “plant factory” attracts scientists and technologists for the challenging features of low production cost, product safety and easy scale up. Once engineered, a plant is among the cheapest and easiest eukaryotic system to be bred with simple know-how, using nutrients, water and light. Molecules that are currently being produced in plants vary from industrial and pharmaceutical proteins, including medical diagnostics proteins and vaccine antigens, to nutritional supplements such as vitamins, carbohydrates and biopolymers. Convergence among disciplines as distant as plant physiology and pharmacology and, more recently, as omic sciences, bioinformatics and nanotechnology, increases the options of research on the plant cell factory. “Farming for Pharming” biologics and small-molecule medicines is a challenging area of plant biotechnology that may break the limits of current standard production technologies. The recent success on Ebola fighting with plant-made antibodies put a spotlight on the enormous potential of next generation herbal medicines made especially in the name of the guiding principle of reduction of costs, hence reduction of disparities of health rights and as a tool to guarantee adequate health protection in developing countries. English plant molecular farming Metabolic Engineering transient expression Genetic Engineering recombinant protein biopharmaceuticals Plant factory Biobetter 2-88945-051-1 Edward P. Rybicki auth Eugenio Benvenuto auth Rosella Franconi auth Kazuhito Fujiyama auth |
language |
English |
format |
eBook |
author |
Domenico De Martinis |
spellingShingle |
Domenico De Martinis Engineering the Plant Factory for the Production of Biologics and Small-Molecule Medicines Frontiers Research Topics |
author_facet |
Domenico De Martinis Edward P. Rybicki Eugenio Benvenuto Rosella Franconi Kazuhito Fujiyama |
author_variant |
d d m ddm |
author2 |
Edward P. Rybicki Eugenio Benvenuto Rosella Franconi Kazuhito Fujiyama |
author2_variant |
e p r epr e b eb r f rf k f kf |
author_sort |
Domenico De Martinis |
title |
Engineering the Plant Factory for the Production of Biologics and Small-Molecule Medicines |
title_full |
Engineering the Plant Factory for the Production of Biologics and Small-Molecule Medicines |
title_fullStr |
Engineering the Plant Factory for the Production of Biologics and Small-Molecule Medicines |
title_full_unstemmed |
Engineering the Plant Factory for the Production of Biologics and Small-Molecule Medicines |
title_auth |
Engineering the Plant Factory for the Production of Biologics and Small-Molecule Medicines |
title_new |
Engineering the Plant Factory for the Production of Biologics and Small-Molecule Medicines |
title_sort |
engineering the plant factory for the production of biologics and small-molecule medicines |
series |
Frontiers Research Topics |
series2 |
Frontiers Research Topics |
publisher |
Frontiers Media SA |
publishDate |
2017 |
physical |
1 electronic resource (377 p.) |
isbn |
2-88945-051-1 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT domenicodemartinis engineeringtheplantfactoryfortheproductionofbiologicsandsmallmoleculemedicines AT edwardprybicki engineeringtheplantfactoryfortheproductionofbiologicsandsmallmoleculemedicines AT eugeniobenvenuto engineeringtheplantfactoryfortheproductionofbiologicsandsmallmoleculemedicines AT rosellafranconi engineeringtheplantfactoryfortheproductionofbiologicsandsmallmoleculemedicines AT kazuhitofujiyama engineeringtheplantfactoryfortheproductionofbiologicsandsmallmoleculemedicines |
status_str |
n |
ids_txt_mv |
(CKB)3800000000216394 (oapen)https://directory.doabooks.org/handle/20.500.12854/46423 (EXLCZ)993800000000216394 |
carrierType_str_mv |
cr |
hierarchy_parent_title |
Frontiers Research Topics |
is_hierarchy_title |
Engineering the Plant Factory for the Production of Biologics and Small-Molecule Medicines |
container_title |
Frontiers Research Topics |
author2_original_writing_str_mv |
noLinkedField noLinkedField noLinkedField noLinkedField |
_version_ |
1796648768364347393 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>05512nam-a2200409z--4500</leader><controlfield tag="001">993546517104498</controlfield><controlfield tag="005">20231214132845.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202102s2017 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)3800000000216394</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/46423</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)993800000000216394</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Domenico De Martinis</subfield><subfield code="4">auth</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Engineering the Plant Factory for the Production of Biologics and Small-Molecule Medicines</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">Frontiers Media SA</subfield><subfield code="c">2017</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (377 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Frontiers Research Topics</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Plant gene transfer achieved in the early ‘80s paved the way for the exploitation of the potential of gene engineering to add novel agronomic traits and/or to design plants as factories for high added value molecules. For this latter area of research, the term "Molecular Farming" was coined in reference to agricultural applications in that major crops like maize and tobacco were originally used basically for pharma applications. The concept of the “green biofactory” implies different advantages over the typical cell factories based on animal cell or microbial cultures already when considering the investment and managing costs of fermenters. Although yield, stability, and quality of the molecules may vary among different heterologous systems and plants are competitive on a case-to-case basis, still the “plant factory” attracts scientists and technologists for the challenging features of low production cost, product safety and easy scale up. Once engineered, a plant is among the cheapest and easiest eukaryotic system to be bred with simple know-how, using nutrients, water and light. Molecules that are currently being produced in plants vary from industrial and pharmaceutical proteins, including medical diagnostics proteins and vaccine antigens, to nutritional supplements such as vitamins, carbohydrates and biopolymers. Convergence among disciplines as distant as plant physiology and pharmacology and, more recently, as omic sciences, bioinformatics and nanotechnology, increases the options of research on the plant cell factory. “Farming for Pharming” biologics and small-molecule medicines is a challenging area of plant biotechnology that may break the limits of current standard production technologies. The recent success on Ebola fighting with plant-made antibodies put a spotlight on the enormous potential of next generation herbal medicines made especially in the name of the guiding principle of reduction of costs, hence reduction of disparities of health rights and as a tool to guarantee adequate health protection in developing countries.Plant gene transfer achieved in the early ‘80s paved the way for the exploitation of the potential of gene engineering to add novel agronomic traits and/or to design plants as factories for high added value molecules. For this latter area of research, the term "Molecular Farming" was coined in reference to agricultural applications in that major crops like maize and tobacco were originally used basically for pharma applications. The concept of the “green biofactory” implies different advantages over the typical cell factories based on animal cell or microbial cultures already when considering the investment and managing costs of fermenters. Although yield, stability, and quality of the molecules may vary among different heterologous systems and plants are competitive on a case-to-case basis, still the “plant factory” attracts scientists and technologists for the challenging features of low production cost, product safety and easy scale up. Once engineered, a plant is among the cheapest and easiest eukaryotic system to be bred with simple know-how, using nutrients, water and light. Molecules that are currently being produced in plants vary from industrial and pharmaceutical proteins, including medical diagnostics proteins and vaccine antigens, to nutritional supplements such as vitamins, carbohydrates and biopolymers. Convergence among disciplines as distant as plant physiology and pharmacology and, more recently, as omic sciences, bioinformatics and nanotechnology, increases the options of research on the plant cell factory. “Farming for Pharming” biologics and small-molecule medicines is a challenging area of plant biotechnology that may break the limits of current standard production technologies. The recent success on Ebola fighting with plant-made antibodies put a spotlight on the enormous potential of next generation herbal medicines made especially in the name of the guiding principle of reduction of costs, hence reduction of disparities of health rights and as a tool to guarantee adequate health protection in developing countries.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">plant molecular farming</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Metabolic Engineering</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">transient expression</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Genetic Engineering</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">recombinant protein</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">biopharmaceuticals</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Plant factory</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Biobetter</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">2-88945-051-1</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Edward P. Rybicki</subfield><subfield code="4">auth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Eugenio Benvenuto</subfield><subfield code="4">auth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rosella Franconi</subfield><subfield code="4">auth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kazuhito Fujiyama</subfield><subfield code="4">auth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:34:10 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2017-09-30 19:47:25 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338267660004498&Force_direct=true</subfield><subfield code="Z">5338267660004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338267660004498</subfield></datafield></record></collection> |